OBJECTIVES: To develop a prognostic nomogram to predict the freedom from recurrence for @entity1 treated with permanent prostate brachytherapy for @entity263 . METHODS: We performed a retrospective analysis of 920 @entity1 treated with permanent prostate brachytherapy between 1992 and 2000. The clinical parameters included clinical stage, biopsy Gleason sum, pretreatment @entity1486 (PSA) value, and administration of external beam radiation. @entity1 who received neoadjuvant @entity342 deprivation therapy were excluded. Failure was defined as any post-treatment administration of @entity342 deprivation, clinical relapse, or biochemical failure, defined as three PSA rises. @entity1 with fewer than three PSA rises were censored at the time of the first PSA rise. Data from two outside institutions served as validation. RESULTS: A nomogram that predicts the probability of remaining free from biochemical recurrence for 5 years after brachytherapy without adjuvant hormonal therapy was developed using Cox proportional hazards regression analysis. External validation revealed a concordance index of 0.61 to 0.64, and calibration of the nomogram suggested confidence limits of +5% to -30%. CONCLUSIONS: The pretreatment nomogram we developed may be useful to physicians and @entity1 in estimating the probability of successful treatment 5 years after brachytherapy for clinically @entity263 .

Pretreatment nomogram for predicting freedom from recurrence after permanent prostate brachytherapy in XXXX .

@entity1 :: ('9606', 'Species') :: ['Patients', 'patients'] @entity263 :: ('MESH:D011471', 'Disease') :: ['localized prostate cancer'] @entity342 :: ('CHEBI:50113', 'Chemical') :: ['androgen'] @entity1486 :: ('354', 'Gene') :: ['prostate-specific antigen']
@entity263 :: (MESH:D011471,Disease) :: ['prostate cancer']
